Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
The purpose of this study is to investigate if co-treatment of acromegalic patients, who
 beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will
 improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can
 be obtained at a neutral cost as compared to SA mono therapy.

 Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and
 intramyocellular fat.
Inclusion Criteria:

 -  Age > 18

 -  Diagnosed with acromegaly

 -  Safe anticonceptive for fertile women

 -  Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH <
 0.5 µg/l.)

 Exclusion Criteria:

 -  Pregnancy

 -  Liver disease

 -  Diabetes mellitus type I

 -  Magnetic or electronic implants